T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review

RATIONALE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of EGFR mutation positive advanced nonsmall cell lung cancer (NSCLC); however, acquired resistance is known to develop during these treatments. Among these mechanisms, histological...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusaba, Yusaku, Takeda, Yuichiro, Abe, Sakurako, Tsukada, Akinari, Naka, Go
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371571/
https://www.ncbi.nlm.nih.gov/pubmed/35960133
http://dx.doi.org/10.1097/MD.0000000000029682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371571/
https://www.ncbi.nlm.nih.gov/pubmed/35960133
http://dx.doi.org/10.1097/MD.0000000000029682

Ejemplares similares